NASDAQ$DMRA
Damora Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings ·
Briefing
DM Therapeutics reported Q4 2024 a net loss of $2.5M.
For Q4 2024, DM Therapeutics reported net loss was $2.5M. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $2.5M.
- MD&A highlights operating priorities, liquidity, and sector risks.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Galecto Inc · Revenue · Quarterly
$0
Forward guidance
Outlook emphasizes clinical milestones, cash runway, and R&D spend.
Tailwinds
- Pipeline progress and partnership economics.
- Balance-sheet flexibility where noted in the release.
Headwinds
- Operating losses until commercialization.
- Trial, regulatory, and financing risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q4 2024
-0.3%
Avg return
Earnings day
+7.9%
Avg return
5 days after
-14.2%
Avg return
30 days after
43%
3 / 7 earnings
Positive
+4.3%
Q4 2020
Best reaction
-8.1%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +4.3% | +7.6% | -10.2% | |
| Q4 2024 | -1.4% | +56.2% | -43.4% | |
| Q3 2024 | -1.5% | +2.0% | -22.6% | |
| Q2 2024 | -2.1% | +11.5% | +0.9% | |
| Q4 2023 | +2.5% | -11.5% | -10.5% | |
| Q4 2022 | -8.1% | -7.7% | -9.1% | |
| Q4 2020 | +4.3% | -3.0% | -4.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro